Potential of new therapies like Anti-PD1 in kidney cancer

Current Treatment Options in Oncology

Volumn 15, Issue 1, 2014, Pages 137-146

  Gunturi, Anasuya ^b   McDermott, David F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Metastatic RCC; Nivolumab; PD 1; PD L1; Targeted immunotherapy

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EVEROLIMUS; INTERLEUKIN 21; IPILIMUMAB; LAMBROLIZUMAB; LIRILUMAB; MK 3475; MPDL 3280A; MPDL3280A; NIVOLUMAB; PAZOPANIB; PD 1 INHIBITOR; PD L1 INHIBITOR; SUNITINIB; TICILIMUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTHRALGIA; ARTICLE; CANCER PROGNOSIS; DIARRHEA; DYSPNEA; FATIGUE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; IMMUNOTHERAPY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROTEIN EXPRESSION; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; TREATMENT RESPONSE; TUMOR CELL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84894650643     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-013-0268-y     Document Type: Article

References (26)

1. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19:309-14.
2. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293-7.
3. Thompson RH, Dong H, Lohse CM. Leibovich, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757-61.
4. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174-9.
5. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent Anti-Programmed Death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-75.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of Anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54. In this study, Topalian et al. describe for the first time a PD-1 blocking agent (an Anti-PD-1 antibody) that generated durable objective responses in patients with advanced RCC, melanoma, and non-small cell lung cancer.
7. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of Anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012. In this study by Brahmer et al. Anti-PD-L1 antibody resulted in an objective response rate of 6 %-17% with durability in advanced RCC, melanoma, and non-small cell lung cancer.
8. Topalian SL. Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial. Am Soc Clin Oncol. 2013. [Abstract #3002].
9. Drake CG. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. Am Soc Clin Oncol. 2013. [Abstract #4514].
10. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44. In this study by Hamid et al. a novel Anti-PD-1 antibody was shown to produce durable objective responses in patients with advanced melanoma, and interestingly, the response rate did not differ significantly between patients who had received prior Anti-CTLA-4 antibody treatment and those who had not.
11. Herbst RS. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Am Soc Clin Oncol. 2013. [Abstract #3000].
12. Cho DC. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Am Soc Clin Oncol. 2013. [Abstract #4505].
13. Grosso J. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (Anti-PD-1, BMS-936558, ONO-4538). Am Soc Clin Oncol. 2013. [Abstract #3016].
14. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616-22.
15. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (Anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-30.
16. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005-16.
17. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-47.
18. Infante JR. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. Am Soc Clin Oncol. 2013. [Abstract #3044].
19. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-33. In this study, Wolchok et al. describe for the first time the effect of Anti-PD-1 and Anti-CTLA-4 antibody combination therapy. In patients with advanced melanoma, the objective response rate was as high as 53%, and treatment-related adverse events were manageable and generally reversible.
20. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207-25 [Review].
21. Lissoni P, Malugani F, Bonfanti A, et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents. 2001;15:140-4.
22. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15:2148-57.
23. Rini BI, Stein M, Shannon P, et al. Phase I dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011;117:758-67.
24. Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120:4317-23.
25. Benson Jr DM, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the Anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120:4324-33.
26. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005;175:2261-9.